Skip to main content
. 2023 Mar 21;25:29. doi: 10.1186/s13058-023-01631-6

Table 1.

Clinicopathological variables in metastatic breast cancer patients at baseline

Included (136) % Excluded (20) %
Age, median (range) 65 (40–90) 65 (45–82)
 < 50 65 48 10 50
 ≥ 50 71 52 10 50
Baseline ECOG
0 75 57 16 90
1 36 27 1 5
2 21 16 1 5
Missing 4 2
PT NHG
I-II 68 62 10 71
III 42 38 4 29
Missing 26 6
PT tumor size
1 49 38 8 44
2 46 36 5 28
3 17 13 3 17
4 17 13 2 11
Missing 7 2
PT node status
negative 39 33 5 28
positive 79 67 13 72
missing 18 2
Breast cancer subtype
ER + HER2- 94 71 11 61
HER2 +  15 11 5 28
ER- HER2- 24 18 2 11
Missing 3 2
Metastasis-free interval (years)
0 28 21 3 15
 > 0–3 25 18 3 15
 ≥ 3 83 61 14 70
Missing 0 0
Metastatic sites, number
 < 3 96 71 13 65
 ≥ 3 40 29 7 35
Missing 0 0
Site of metastasis
Non-Visceral 56 41 9 45
Visceral 80 59 11 55
Missing 0 0
1st line of treatment for MBC
Endocrine 55 43 3 19
Chemotherapy 60 47 11 69
HER2-targeted 13 10 2 12
Missing 8 4
CTC
 < 5 65 49 8 44
 ≥ 5 69 51 10 56
Missing 2 2
One or more CTC clusters
No 108 81 14 78
Yes 26 19 4 22
Missing 2 2

CTC circulating tumor cells; ECOG Eastern Cooperative Oncology Group; ER estrogen receptor; HER2 human epidermal growth factor; MBC metastatic breast cancer; NHG Nottingham histological grade; PT primary tumor